Global CNS Specific Antisense Oligonucleotide Market to Surpass US$ 6.8 Billion by 2026 – Coherent Market Insights


SEATTLE, Feb. 08, 2019 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global CNS specific antisense oligonucleotide market is valued at US$ 883.7 million in 2017, and is projected to exhibit a CAGR of 24.9% over the forecast period (2018 – 2026).

Key Trends and Analysis of the CNS specific antisense oligonucleotide Market:

Key trends in market are rich product pipeline, and launch of new products for rare disease associated with CNS disorders, increasing collaboration between the market players, government support for antisense oligonucleotides, and high prevalence of neurodegenerative disorders.

Request Sample Copy of this Report @

Market players are actively investing in research for developing CNS specific antisense oligonucleotide for the treatment of various rare diseases. Moreover, the players are committed to offer new and improved products in order to address the critical unmet needs of patients. For instance, in July 2017, Ionis and Biogen received approval from Health Canada for its drug, Spinraza (Nusinersen), for the treatment of spinal muscular atrophy.

Furthermore, key players operating in the market are focused on adopting acquisition strategies or collaborations in order to gain access to innovative products and expand their product offerings in the potential markets. For instance, in October 2018, Ionis Pharmaceuticals, Inc. collaborated with Roche to develop IONIS-FB-LRx for the treatment of complement-mediated diseases. This collaboration will positively influence Ionis' leadership in RNA-targeted therapeutics to develop IONIS-FB-LRx targeting Factor B (FB) for a broad range of diseases.

However, toxic effects and high cost of treatment and development are expected to hinder the market growth. For instance, Inotersen manufactured by Ionis Pharmaceuticals in partnership with Akcea Therapeutics, received approval for hereditary Transthyretin Amyloidosis Polyneuropathy indication and the price for it is US$ 450,000, annually.

To know the latest trends and insights prevalent in this market, click the link below:

Key Market Takeaways:

  • The CNS specific antisense oligonucleotide market is expected to exhibit a CAGR of 24.9 % during the forecast period (2018 – 2026), which is attributed to increasing number of neurodegenerative diseases and rare disease associated with it. According to the report published, in January 2019, by Orphanet report series, around 2.7 prevalence and 0.38 incidences per 100,000 persons of Huntington’s disease was reported globally.
  • Market growth is attributed to the launch of novel antisense oligonucleotide therapy for the treatment of rare disease. For instance, in October 2018, Alnylam Pharmaceuticals, Inc. received the U.S. Food and Drug Administration (FDA) approval for its ONPATTRO (patisiran) lipid complex injection, for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
  • Key players in the market are focused on adopting merger and acquisition strategies to enhance their product portfolio, which in turn is expected to propel the market growth over the forecast period. For instance, in November 2018, Q-State Biosciences, Inc. joined with Pairnomix, LLC to create the innovative and breakthrough medicine for the treatment of rare and devastating central nervous system diseases.
  • Key players operating in the global CNS specific antisense oligonucleotide market include, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Biogen Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Stroke Therapeutic Inc., Dynacure, ProQR Therapeutics N.V., Q-STATE BIOSCIENCES, INC.

Inquire before Buying

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Data